MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
September 07, 2022 16:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., Sept. 07, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results
August 10, 2022 16:05 ET
|
MaxCyte, Inc
45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- MaxCyte,...
MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022
July 15, 2022 08:00 ET
|
MaxCyte, Inc
GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs
July 12, 2022 08:00 ET
|
MaxCyte, Inc
GAITHERSBURG, Md., July 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 13, 2022 16:30 ET
|
MaxCyte, Inc
GAITHERSBURG, Md., May 13, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte Reports First Quarter Financial Results
May 09, 2022 16:05 ET
|
MaxCyte, Inc
GAITHERSBURG, Md., May 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte to Participate in Upcoming Investor Conferences
May 03, 2022 16:05 ET
|
MaxCyte, Inc
GAITHERSBURG, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022
April 20, 2022 16:05 ET
|
MaxCyte, Inc
GAITHERSBURG, Md., April 20, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 15, 2022 09:00 ET
|
MaxCyte, Inc
GAITHERSBURG, Md., April 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform...
MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue
April 12, 2022 16:05 ET
|
MaxCyte, Inc
GAITHERSBURG, Md., April 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...